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Cardiovascular disease (CVD) is the leading cause of death among women in the
United States (Sowers, 1998). The incidence of CVD is not as common in
premenopausal women as it is in men. However, the incidence increases among women
at the onset of menopause, probably due to reduced levels of female sex hormones
(Sowers,1998). Menopause is a natural biological phenomena marked by estrogen
withdrawal, which is regarded as a risk factor for coronary heart disease. Statistics show
that CVD risk doubles in women entering spontaneous menopause at the usual age, and
quadruples in women following early menopause, such as those undergoing ovariectomy
(Sullivan, 1996). As a consequence, one third of women between 50 and 75 years of
age have CVD, which accounts for more than 50% of all deaths among females each
year (Giardina, 1998).
Estrogen seems to have a protective effect against the risk of CVD (Ottesen &
Sorensen, 1997). Estrogen withdrawal affects lipid metabolism in many ways including
decreased HDL-cholesterol, and increased total and LDL-cholesterol (Sullivan, 1996).
In postmenopausal women, LDL-choJesterol concentration tends to be higher than age-
matched men (Sullivan, 1996). The net result is a change in HDL-cholesterol and LDL-
cholesterol concentrations, leading to an associated increase in CVD risk. Currently,
estrogen replacement therapy is prescribed for many postmenopausal women. However,
hormone replacement therapy is suspected to increase the risk of cancer development,
and is not recommended for all postmenopausal women (Barrett-Connor & Grady,
1998).
Chromium status may also affect CVD risk among postmenopausal women
(Davies et aI., 1997). Generally, poor mineral status including chromium has been
reported in older adults (Wood et aI., 1995). Low chromium status may be due in part to
poor dietary intake (Wood et al., 1995) and to age related tissue loss (Wallach & Verch,
1986).
Poor chromium status can result in a decline in many physiological functions
(Chapman et aI., 1996). Insufficient dietary chromium intake has been reported to result
in symptoms similar to those seen in CVD and diabetes (Anderson, 1997). In humans,
some studies reported that chromium supplementation significantly reduced total
cholesterol and LDL-cholesterol concentrations, and increased HDL-cholesterol
concentration (Mertz, 1993; Riales & Albrink, 1981). However, other studies found
insignificant or only partial effects of chromium on serum lipids (Potter et aI., 1985;
Uusitupa, 1983).
A significant reduction in serum triglycerides (TG) concentration was reported in
non-insulin dependent diabetes mellitus (NIDDM) patients supplemented with
chromium (Lee & Reasner, 1994). Rats fed chromium also showed an insulin
hyperresponsiveness with insulin secretory response nearly two fold (Striffler et a1.,
1995). Hyperglycemia is associated with hypertriglyceridemia and this association may
increase postmenopausal CVD risk (Stout, 1990). Since chromium deficiency may
increase glucose intolerance, chromium deficiency may explain the association between
age-related glucose intolerance and the increase in the risk for CVD development
(Davies et aI., 1997), and thus poor chromium status may be a risk factor for increased
CVD in postmenopausal women.
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The mechanism of chromium's action on glucose and lipid metabolism is not
clear (Mertz, 1993). Chromium helps control blood glucose by increasing insulin action
through binding to insulin receptors in peripheral tissue. Chromium deficiency has been
reported to decrease cyclic adenosine monophosphate-dependent phosphodiesterase
activity (cAMP-PDE) which is associated with increased tissue insulin resistance
(Striffler et aI., 1995). Controlling glucose metabolism may be the key for chromium
action on lipid metabolism (Anderson et al., 1997).
Purpose
The purpose of this study was to investigate the effects of twelve-week
chromium supplementation at a level of 200 Ilglday on serum lipids (total cholesterol,
HDL-cholesterol, LDL-cholesterol and TO), apolipoproteins (apo A-I and apo-B),
estradiol, glucose and insulin concentrations in postmenopausal women with elevated
serum cholesterol, who were not using estrogen replacement therapy.
Hypothesis
1-10 1: there will be no significant effect due to twelve-week supplementation with 200
lAg/day of chromium on serum lipids (total cholesterol, HDL-cholesterol, LDL-
cholesterol, and TO) and apolipoproteins (apo A-I, apo B).
1-10 2: there will be no significant effect due to twelve-week supplementation with 200
Ilg/day of chromium on serum insulin and serum fasting glucose.
1-103: there will be no significant effect due to twelve-week supplementation with 200
Ilg/day of chromium on serum estradiol.
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Assumptions
It was assumed that:
1: the subjects accurately reported their use of medications, vitamin and mineral
supplements;
2: the subjects accurately reported their food frequency questionnaires;
3: the subjects took their supplements as directed;
4: the subjects fasted twelve hours before each blood collection;
5: the subjects did not change their eating patterns during the course of the study;
6: the chromium supplements did not interact chemically with the lactose filling in the
supplements, and consequently remained biologically available;
7: all the antropometric measurements and sample analyses were accurate and reliable.
Limitations
The limitations of this study included:
1: the low number of participants in the study due to the difficulty in finding
postmenopausal women with elevated cholesterol who were not on estrogen replacement
therapy in the city of Stillwater, OK and surrounding area;
2: the noncompliance of some participants in taking the supplements as directed,
following the overnight fasting instructions, and water consumption prior to blood
collection;




Incidence of Cardiovascular Disease at Menopause
Since the beginning of this century women's life expectancy has increased from
62 to almost 80 years of age (Ottesen & Sorensen, 1997). On the other hand, the
average age of menopause has remained around 51 years of age (Ottesen & Sorensen,
1997). As a consequence, women are now spending a longer period of life in the state
of estrogen deficiency (Ottesen & Sorensen, 1997). By the year 2030 it is expected that
about 1.2 billion women worldwide will be postmenopausal (Ottesen & Sorensen,
1997).
Cardiovascular disease (CVD) is the leading cause of death in postmenopausal
women (Ottesen & Sorensen, 1997). One third of the women between 50 and 75 years
of age have some forms of CVD. This accounts for more than 50% of aU annual deaths
among women (Giardina, 1998). The impact of CVD on postmenopausal women's life is
that it is more lethal and less aggressively treated in women than men (Giardina, 1998).
This is shown by the fact that twice as many women die from heart disease as from all
forms of cancer combined (Giardina, 1998).
Biochemical Changes at Menopause
Description of Estrogen Loss at Menopause
The period between puberty and menopause is marked with a continuous
variation in the level of serum estrogen throughout the menstrual cycle (Barrett-Connor
& Bush, 1991). During the follicular phase, estrogen concentration is higher than
progesterone. During the luteal phase, both estrogen and progesterone levels become
5
high without any dominance for either (Barrett-Connor & Bush, 1991). At the
perimenopausal period serum estrogen level begins to decline (Barrett-Connor & Bush,
1991). Due to ovarian failure at menopause,. estradiol is replaced by estrone, a less
active fonn of estrogen produced in the adipose tissue (Barrett-Connor & Bush, 1991).
With advancing age, estrogen continues its gradual withdrawal, but in a slower manner
(Barrett-Connor & Bush, 1991).
These marked changes have many effects on postmenopausal women IS health,
especially on the lipid metabolism, which in turn affects the cardiovascular system
(Barrett-Conor & Bush, 1991). Some changes in lipids observed in postmenopausal
women are increased serum TG, total cholesterol, LDL-cholesterol, and apo B, and
decreased HDL-cholesterol, and apo A, increased insulin concentration and resistance,
and decreased insulin peripheral utilization (Nasr & Breckwoldt, 1998).
Changes in Total and LDL-Cholesterol at Menopause
Cholesterol is a fat-like substance involved in the synthesis of cell membranes,
honnones and other compounds. In the circulation, cholesterol is carried in particles
containing lipids and proteins known as lipoproteins among which are the low density
lipoprotein (LDL) and the high density lipoprotein (HDL). The LDL is the major
atherogenic class, containing 60% to 70% of the total serum cholesterol. LDL contains
apolipoprotein B (apo B), which possesses an atherogenic property (Knopp et aI., 1994).
Cholesterol concentration is known to increase with age. However, major gender
differences exist in the age-related changes. In men, circulating cholesterol increases in
concentration until 50 years of age where it starts to decline. In contrary to what is seen
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in men, cholesterol concentration continues to .rise in women even after menopause
(Corti et al., 1997).
For the general population, total serum cholesterol concentration below 200
mg/dl is classified as desirable. A total serum cholesterol concentration of 200 to 239
mg/dl is classified as being borderline to high risk. A total serum cholesterol
concentration above 240 mg/dl is classified as high, and the risk of CVD rises sharply
above this level (The Expert Panel, 1988). Elevated total serum cholesterol is an
important risk factor of CVD, and a 10% to 15% reduction in elevated total serum
cholesterol may reduce CVD risk by 20% to 30% (The Expert Panel, 1988).
Since LDL contains the major fraction of serum total cholesterol, it is expected
to be the major component that enhances CVD risk (Acra et al., 1994). An LDL-
cholesterol concentration of 160 mg/dl or greater is classified as high risk, and this LDL-
cholesterol concentration corresponds to a total serum cholesterol concentration of 240
mg/dl (The Expert Panel, 1988). Estrogen lowers LDL concentration by increasing its
clearance from plasma (Nabulsi et aI., 1993). Estradiol withdrawal decreases the rate of
LDL catabolism (Corti et aI., 1997), but has no effect on LDL synthesis (Walsh et al.,
1991). Estrogen withdrawal results in higher LDL concentration (Walsh et aI., 1991).
The decrease in LDL catabolic rate is not due to a reduced binding affinity of LDL
particles to receptors. Rather, decreased LDL catabolism seems to be mediated via a
decrease in the expression of LDL-cholesterol hepatic receptors (Corti et aI., 1997). The
net effect of estrogen withdrawal is an increase in the circulating LDL-cholesterol
concentration, which results in an increased cholesterol influx into the arterial wall (Nasr
& Breckwoldt, 1998).
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Changes in HDL-Cholesterol. Apolipoprotein A-I and B at Menopause
The HDL contains 20% to 30% of total cholesterol (The Expert Panel, 1988).
The cholesterol content of HDL is inversely related to CVD incidence (Schaefer et a1.,
1982). HDL also contains apolipoprotein A-I (apo A-I) which comprises almost 90% of
the HDL protein mass, and to which the anti-atherogenic property of HDL-cholesterol is
attributed (Schaefer et al., 1982). Within the general population, an HDL-cholesterol
concentration below 35 mg/ell is classified as low. Such a concentration or below is
considered to be a risk factor for CVD (The Expert Panel, 1988). It was reported that
the cardioprotective role of HDL is about two fold stronger than the atherogenic role of
LDL. An increase of 1 mg/dl of circulating HDL-cholesterol is associated with a
decrease of 5% in CVD risk factor (Kannel, 1987).
The role of HDL is to remove excess tissue cholesterol via transfer from the cell
membrane to the liver, which implies that HDL concentration is inversely related to the
risk of CVD development (Wakatsuki & Sagara, 1995). Estrogen withdrawal results in
a decreased circulating HDL concentration (Barrett-Connor & Bush, 1991). This may
be mediated through the effect of estrogen on plasma hepatic triglyceride lipase. The
absence of estrogen increases plasma hepatic triglyceride lipase concentration, which
reduces the circulating concentration of HDL (Wakatsuki & Sagara, 1995). Plasma
hepatic triglyceride lipase decreases circulating HDL by causing the removal of HDL
particles from the circulation into the liver (Wakatsuki & Sagara, 1995).
Low HDL-cholesterol concentration was reported to be associated with high
plasma TG concentration and high hepatic triglyceride lipase concentration (Brinton et
aI., 1991), a condition appearing in the absence of estrogen (Wakatsuki & Sagara, 1995).
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It has been reported that postmenopausal women have higher TO (WU et al., 1990).
During hypertriglyceridemia, TG concentration increases in the lIDL core. TG is
readily hydrolyzed by hepatic tri.glyceride lipase, which causes the catabolism and
removal of HDL (Brinton et a1., 1991).
Apo A-I is a major constituent ofHDL. As much as 90% of apo A-I is found in
HDL (Schaefer et aI., 1982). As a part ofHDL, apo A-I is reported to activate
lecithin:cholesterol acyltransferase (LCAT), which is the enzyme responsible for
cholesterol esterification in plasma (Schaefer et aI., 1982). LCAT activates HDL to
transport cholesterol from peripheral tissues to the liver for subsequent excretion
(Schemthaner et aI., 1983). The net result of a high apo A-I is an antiatherogenic effect
(Schaefer et aI., 1982).
Estrogen loss affects apo A-I by more than one mechanism. Estrogen loss
increases hepatic triglyceride lipase concentration, which catabolizes apo A-I (Brinton et
aI., 1991). This would decrease apo A-I circulating level (Schaefer et aI., 1982). On the
other hand, it was reported that estrogen increases apo A-I circulating concentration by
increasing its production (Walsh et al., 1994).
Apo B is an apolipoprotein found in LDL. An elevation of apo B content in
LDL precursor is associated with increasing atherosclerosis (Knopp et a1. 1994), and
reflects a risk factor for CVD (Lamarche et aI., 1998). Estrogen was reported to
decrease circulating concentration of apo B by increasing LDL receptors that recognize
apo B (Knopp et aI., 1994).
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Changes in Triglycerides at Menopause
Hypertriglyceridemia is divided into two categories: mild to moderate for TO
concentrations of 250 to 700 mg/dl, and moderate to severe for TG concentrations of
700 to 1000 mg/dl (Kuczmarski, 1998). Although some studies have found the
relationship between plasma TO and CVD controversial (The Expert Panel, 1988), the
Framingham study reported an increased risk of CVD with increasing plasma TO
concentration. This relationship is stronger in women than in men (Davignon & Cohn,
1996), and especially in postmenopausal women (WU et a1., 1990).
Even for those studies denying any direct relationship of TG concentration to
CVD, high plasma TG concentration is associated to lipoprotein abnormalities, such as
low HDL-cholesterol, apo A-I and high apo B (The Expert Panel, 1988). In other
studies, high serum TO concentration was reported to be a strong predictor of CVD,
independent of lipoprotein changes (Davignon & Cohn, 1996). The atherogenic
property of TG is related in part to the type of lipoprotein carrying the TO (Davignon &
Cohn, 1996).
Hypertriglyceridemia and hyperglycemia are closely associated. TO formation is
in part due to de novo synthesis of fatty acids from blood glucose via the lipogenesis
pathway (Aarsland et aI., 1996). In hypertriglyceridemia, acetyl coenzyme A-
carboxylase, which is the rate-limiting enzyme in fatty acid synthesis from glucose via
pyruvate, is highly activated. This activation increases the influx of synthesized fatty
acids into the liver to fonn TG (Davignon & Cohn, 1996). However, it was reported
that hepatic TG formation mainly results from the re-esterification of fatty acids cleared
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from plasma and delivered to the liver, rather than from de novo synthesized fatty acids
(Aarsland et al., 1996).
Insulin resistance is common in elderly women (Sowers, 1998). Insulin
resistance could increase the concentration of TO since high insulin concentration was
reported to inhibit lipolysis (Coppack et al., 1994). Insulin was also reported to promote
hepatic TO release (Berthezene, 1992).
Diabetes as a Risk Factor for CVD
Diabetes was reported to increase the risk of CVD three fold in women and thus
places them at the same risk for CVD as men of the same age (Kannel, 1987). The
Framingham study reported that, for individuals 50 to' 80 years of age, diabetes is a
greater risk factor for CVD in women than in men. Risk factors for CVD in women
with diabetes, including dyslipidemia, were reported to be higher than in non-diabetic
women (Sowers, 1998). In addition, preexisting CVD risk factors become more
aggravated at the onset of diabetes (Kannel, 1987). An epidemiological study on
women with CVD reported that the mortality rate in women with diabetes (mostly type
2) is significantly higher than the rate without diabetes (Sowers, 1998). The primary
cause of death from CVD among the NIDDM subject is not fully understood. However,
atherosclerosis is the major factor (Litwak et aI., 1998).
Definition of Non-Insulin Dependent Diabetes Mellitus (NIDDM type 2)
Non-insulin dependent diabetes mellitus (NIDDM), or type 2 diabetes, is a
maturity onset type of diabetes. It occurs after 40 years of age and it is associated with
obesity. NIDDM individuals are characterized with high fasting (Stout, 1990) and
postprandial concentrations of insulin (Howard, 1987). They are also characterized with
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high serum glucose concentration. The reason for the high glucose-high insulin
phenomena is the fact that insulin is unable to induce adequate glucose disposal due to
insulin resistance, which results from a. defect at the cellular level in peripheral tissues
(Howard, 1987).
Lipoprotein Metabolism in NIDDM
Diabetic dyslipidemia may be a major risk factor for CVD in NIDDM (Lee &
Reasner, 1994). Hyperinsulinemia may enhance the risk of CVD by adversely affecting
the concentration and composition of lipoproteins (Stout, 1990). The catabolic rate of
LDL in NIDDM is decreased. High glucose concentration could lead to a nonenzymatic
glycosylation of apo B which affects the interaction of LDL with its receptor, leading to
a lower LDL catabolism. In addition, in NIDDM, the transfer of cholesteryl ester to
LDL is inhibited. The inhibition of cholesteryl ester transfer to LDL leads to an increase
in cholesterol content in LDL (Howard, 1987).
There is a decreased rate of lIDL synthesis in NIDDM. lIDL composition is
also altered. A decrease in the insulin sensitive lipoprotein lipase activity causes a
decrease in the rate ofHD~ formation (King et aI., 1991). As a result, lIDL-cholesterol
concentration is lower in NIDDM subjects (Stout, 1990). Besides, since apo A-I
concentration in HDL is correJated with the lIDL-cholesterol concentration, the
circulating level of apo A-I is also diminished. On the other hand, high TG in HDL is
observed in NIDDM. Hepatic triglyceride lipase activity is increased (Stout, 1990), and
this may contribute to lowering the HDL-cholesterol concentration (Howard, 1987). In
conclusion, the changes in lipoproteins metabolism during NIDDM would increase the
probability that diabetes is a risk factor for CVD development.
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Role of Insulin in Abnormal Lipoprotein Metabolism
There is a negative correlation between HDL and insulin concentration and a
positive correlation between LDL and insulin concentrations. A positive correlation also
exists between TG and insulin concentrations. Insulin is important in lipoprotein
metabolism, but only within limited ranges. Insulin in minimum amounts is needed for
nonnallipoprotein (HDL and LDL) metabolism, lipoprotein lipase production, and for
the hydrolysis of triglycerides by lipoprotein lipase (Stout, 1990). Nevertheless,
hyperinsulinemia leads to metabolic alteration in liver, adipocytes, and muscles, which
influences plasma lipoproteins (HDL and LDL) concentrations and composition
(Howard, 1987).
It seems that there are two different kinds of insulin receptors in muscle tissues,
receptors for metabolic functions and others for cell proliferation. Due to excess insulin
secretion, insulin resistance may develop, and the metabolic activity of insulin becomes
blunt, causing abnormal lipoprotein (HDL and LDL) metabolism, which is a risk factor
for CVD. In the same time the proliferative activity of insulin remains active, causing
arterial resistance which also increases the risk for CVD development (Stout, 1990).
Effect of Hyperglycemia on CVD
Hyperglycemia is related to abnormal low density and high density lipoprotein
metabolism, which is associated with atherogenesis (Lehto et aI., 1997). Hyperglycemia
leads to excessive formation of malonyl CoA, which in tum decreases the transport of
fatty acid to mitochondria in muscle tissue. The result is an elevation of plasma TG and
a subsequent accumulation in li ver leading to abnonnallipoprotein metabolism, which is
considered a risk factor for the development of CVD (Laybutt et at, 1997). On the other
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hand, hyperglycemia leads to de novo synthesis of fatty acid, and eventually to TO
formation, as mentioned earlier (Aarsland et al., 1996).
Hyperglycemia may have other negative effects on the development of CVD. It
was reported that hyperglycemia alters the production of endothelial cell matrix which
contributes to the thickening of the basement membrane (Stout, 1990). This delays cell
replication and increases cell death by enhancing oxidation and glycation, leading to an
increased plaque formation, and consequently higher CVD incidence (Sowers, 1998;
Litwak et a1., 1998).
Chromium in Elderly Nutrition
Nutritional Status and Mineral Requirements for Elderly
Nutrition and health status are interrelated, especially when it comes to the
theory that malnutrition may lead to chronic diseases (Wood et al., 1995).
Undernutrition is well documented in elderly, whether they are apparently healthy, or in
nursing homes. Consumption of less than two thirds of the RDA is common among the
elderly who are 70 years of age and older (Mowe et al., 1994). This is very important
since the elderly population is a rapidly growing segment of the US population. It is
estimated that by the year 2030,25% of the US population will be elderly (Wood et al.,
1995). Living alone and low income status are some of the factors that explain in part
the poor nutritional status of the elderly. However, what is more important is their
limited capability of consuming food. Elderly report that they enjoy food less than
before (Mowe et al., 1994), which potentially increases the risk of mineral deficiency
(Wood et a1., 1995). This could be due to an alteration of appetite following medication,
or age-related change in smell and taste. Poor food intake could be also due to poor
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denture condition, oral health problem, or difficulty in swallowing (Wood et aI., 1995).
Sources of Dietary Chromium
The typical American diet is generally low in chromium (Anderson &
Kozlovsky, 1985). No food is known to be an outstanding source of chromium.
Chromium distribution is almost similar among fruits, vegetables, dairy products, meat
and beverages. Some examples of relatively high chromium containing food are: high
bran breakfast cereals, broccoli, green beans, mushrooms, brewer's yeast, black pepper,
prunes, raisins. nuts and milk colostrum (Anderson, 1988). Foods high in simple sugars
enhances chromium lo~s from the body and are at the same time poor sources of
chromium (Anderson, 1997).
Chromium Intake in Elderly
The ESADDI of chromium is between 50 to 200 Ilglday (Anderson, 1997), and
an adult who consumes 50 Ilg chromium absorbs and retains around 200-500 ng
(Wallach, 1985). Chromium exists in the biological tissues in many fonns. These forms
are ionic, trivalent, and as a part of glucose tolerance factor complex (Wallach, 1985).
Chromium intake in the elderly population was reported to be below the recommended
range (Wood et aI., 1995). This may lead to chromium deficiency and depletion of body
stores among elderly (Wallach, 1985). In addition, it seems that elderly cannot get
adequate chromium intake from diet alone (Wood et al., 1995). For a typical adult
intake, 3000 kcal are needed to provide an amount of 50 Ilg of chromium per day (Wood
et al., 1995; Anderson, 1988). This caloric intake seems to be difficult for the elderly to
achieve, since the average daily caloric intake of elderly is approximately 1871 kcal for
men and 1468 kcal for women (Wood et al., 1995). Adult women consume an average
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of 25 J,lg of chromium a day (Anderson, 1997). Processing may contribute to low
chromium content in food. It is estimated that the chromium concentration of
institutional diet is 16 J,lg per every 1000 kcal (Anderson, 1988), ranging from 5 to 24 tJ.g
per 1000 kcal (Anderson, 1997).
Mineral Loss at Menopause
All tissues show an age related decrease in chromium concentration except lungs
(Davies et a1., 1997). Premenopausal women have a higher chromium tissue content,
probably due to female sex honnones (Davies et al., 1997). Age related chromium loss
may be due to low intake, defect in absorption, excessive urinary loss, or a sudden
decrease in the ability of tissue to retain chromium. Concerning tissue retention, aging
alters chromium distribution in the body by decreasing cellular chromium transport.
The most remarkable decrease in tissue chromium is observed in bone (Wallach &
Verch, 1986). Althought there is no accurate established standard to measure total body
chromium (Lee & Reasner, 1994), one of the largest chromium long term storage
compartments in the body is bone (Thomann et aI., 1994).
Effect of Chromium on Lipid and Glucose Metabolism, and on Weight Reduction
The effect of chromium on blood lipids and glucose metabolism is controversial.
Chromium, in some studies, was reported to improve several risk factors of CVD
including total, LDL and HDL cholesterol, TG, apo B, apo A-I, glucose level and insulin
output in humans and animals. In other studies no or insignificant changes in these
parameters were obtained. Negative results have been attributed to numerous factors
including inadequate amount of chromium supplementation, body mineral status of the
subjects, experimental design and others.
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One randomized study on atherosclerotic patients (average age of 63 years),
some of them having NIDDM, and consuming 250 Jlglday of chromium for eleven
months, reported no significant changes in mean fasting glucose concentration, total
cholesterol, HDL and total TG in both diabetic and non-diabetic subjects. In this study,
a nonsignificant increase in mean fasting glucose concentration was reported among the
diabetic subjects in the chromium treated group. The mean HDL cholesterol serum
concentration significantly increased among the chromium treated group compared to
their initial values (Abraham et aI., 1992).
One similar study was done on men with an average age of 57 years using
adrenergic blockers to lower their blood pressure. Beta blockers are known to decrease
the serum concentration of HDL cholesterol and to increase the concentration o.f TG. In
this study the experimental group consumed an amount of 600 Jlglday of chromium for
two months. Chromium intake increased significantly the HDL cholesterol
concentration compared to the control whereas no significant changes were seen in other
plasma lipids or lipoproteins (Roeback et aI., 1991).
Another randomized double blind trial done on healthy young adults consuming
200 Jlglday of chromium for three months, reported no significant changes in fasting
blood glucose, LDL, HDL, TO and blood insulin between chromium treated and placebo
groups. Within the chromium group, those who had a relatively higher insulin
concentration showed a significant decrease in insulin concentration whereas no
significant changes were seen in fasting glucose concentration or in serum lipids
(Wilson & Gondy, 1995).
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A similar double blind crossover study. done on healthy vo!unteersaging
between the age of 25 to 80 years consuming 200 J.lglday of chromium for a period of 42
days. was reported to significantly decrease total and LDL-cholesterol compared to the
control. Apo B decreased significantly and apo A-I showed a significant elevation in
concentration, whereas HDL cholesterol and TO concentrations showed an insignificant
elevation (Press et al., 1990).
Another 16 week crossover double blind study conducted on healthy and
NIDDM subjects with ages around 45 years, consuming an amount of 200 Ilglday of
chromium for a period of 8 weeks, reported no significant effect for chromium on
glucose tolerance and plasma lipid concentrations. Chromium supplementation tended
to lower total and LDL cholesterol, TG and glucose and to raise HDL cholesterol
concentrations in the NIDDM individuals (Thomas & Gropper, 1996).
A double blind crossover study involving NIDDM patients between 32 and 65
years of age consuming 200 J.lglday of chromium for a period of 2 months showed no
effect of chromium on glucose control, LDL and IIDL cholesterol. The only significant
effect of chromium was observed on plasma TG (Lee & Reasner, 1994).
Another study involved a supplementation of 10 g1day of chromium-containing
substance, in the form of either brewer's yeast (providing 7 J.lglday chromium) or torula
yeast (providing 0.3 Jlglday chromium). Supplements were randomly assigned to
healthy adults having an average age of 51 years, for a period of 12 weeks. The study
reported a significant decrease in glucose concentration following an oral glocose
tolerance test within the brewer's group, but a significant increase within the torula
group. Insulin concentration following the tolerance test did not decrease significantly
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within both groups. However, brewer's yeast significantly decreased plasma TO
concentration but not other serum lipids (Li, 1994).
Two groups of nonnolipidemic and hyperlipipdemic subjects with an average
age of 54 years consuming 20 g of brewer's yeast providing 40 J.lg chromium daily for 8
weeks were compared to each other. The results showed an insignificant decrease in
serum TO concentration among the hyperlipidemic subjects and an insignificant increase
among the nonnolipidemic subjects. Total cholesterol concentration decreased
significantly in both groups, whereas HDL cholesterol concentration significantly
increased in the hyperlipidemic group to the same value of the normolipidemic group
(Elwood et aI., 1982).
NIDDM and non diabetic elderly subjects aging 78 years and older, randomly
consumed 9g/day of either brewer's yeast (10.8 Jlg chromium) or torula yeast (0.45 J.lg
chromium) for 8 weeks. The study showed a significant decrease in glucose
concentration and in insulin secretory response to glucose within the brewer's group
(diabetic and non diabetic), and an insignificant change in the same parameters within
the torula group. Also total cholesterol decreased significantly within the brewer's
group, whereas the TG did not show any significant change in either group (Offenbacher
& Pi-Sunyer, 1980).
A pre-test post-test study on elderly subjects with an average age of 66 years,
having glucose intolerance and supplemented with 200 J.Lg chromium daily for 12 weeks
reported no significant change in plasma glucose and insulin concentrations compared to
pre-test. Lipid parameters did not show any significant change; however, TO tended to
increase and total, HDL and LDL cholesterol tended to decrease (Potter et aI., 1985).
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One double blind crossover study done on NIDDM patients aging between 37
and 68 years and consuming 200 j.lg chromium daily or a placebo reported no significant
change in fasting and 2 hour postprandial blood glucose concentrations in the chromium
group compared to placebo. There were also no significant changes reported in the
fasting insulin, total cholesterol, HDL, LDL and serum TO concentrations in the same
group (Uusitupa et a1., 1983).
Uusitupa et al. also investigated the effects of chromium supplementation on
elderly people with glucose intolerance, between 65 and 74 years of age. Subjects were
supplemented with 160 Jlg chromium daily for a period of six months or a placebo. The
study reported no significant change in the fasting and postprandial blood glucose and
insulin concentrations in either groups, even though insulin concentration tended to be
lower within the chromium group. There were also no significant changes in total, LD~
and HDL cholesterol, TO, apo A-I and apo B (Uusitupa et al., 1992).
On the contrary, a double blind study on healthy men between 31 and 60 years of
age receiving either 100 ~g/day chromium or a placebo for a period of 12 weeks
reported a significant increase in HDL cholesterol concentration, a significant decrease
in TG concentration and no significant change in LDL cholesterol concentration.
Fasting and postprandia] plasma glucose concentrations were significantly lower at 6
weeks and only fasting glucose concentration was lower at 12 weeks within the
chromium group. Insulin concentration also decreased in the chromium supplemented
group at 12 weeks (Riales & Albrink, 1981).
The effect of different dosages of chromium supplementation on NIDDM
subjects was also tested. Subjects between 35 and 65 years of age were randomly
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assigned to either a placebo, 200 Jlglday, or 1000 J.1g1day of chromium for 4 months.
Fasting and postprandial plasma glucose were significantly lower after 2 and 4 months
in the group supplemented with 200 J.1g chromium per day. Fasting insulin was also
significantly lower in both chromium groups after two months. Chromium
supplementation also significantly decreased the total cholesterol at 4 months in the high
chromium group. There was no effect of chromium on HDL cholesterol, TO, or body
weight (Anderson et al., 1997).
Animal studies show the same inconsistency in their results concerning the effect
of chromium supplementation on glucose metabolism and CVD risk factors. A 90 day
randomized trial using rabbits reported a significant reduction in the aortic plaque in the
chromium injected group. Total cholesterol and TG concentrations tended to be lower
in these groups but not in a significant manner. Also chromium increased HDL and
decreased LDL but the differences were not significant (Abraham et al., 1982).
A study on rats fed either a low or high chromium diet for 18 months revealed no
significant change in the fasting plasma glucose concentration between the low and the
high chromium group diet. Postprandial plasma glucose concentration was lower in the
high chromium group at 4 and 8 months but not at 12 months. No significant
differences were also seen in total cholesterol and TG between the two groups. The
study also reported that there was no significant change in the distribution of cholesterol
and TG in LDL and HDL (Donaldson et al., 1985).
Another trial using pigs fed either chromium or placebo for 21 days reported an
increase in plasma cholesterol within the chromium group, whereas plasma glucose was
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not affected. Serum TG and fasting plasma insulin were also reported to decrease in the
chromium group (Amoikon et aI., 1995).
Male rats randomly assigned to a 24 week study and supplemented with either
chromium deficient or chromium diet beside a glucose intolerance-inducing diet,
showed a significant decrease in insulin concentration within the chromium
supplemented group but a lower blood glucose concentration was not significant
(Striffler et aI., 1995). The same author reported a fasting hyperinsulinemia in the low
chromium diet group after 16 weeks in a similar experimental protocol, compared to the
high chromium diet group. Plasma TO concentration tended to be lower within the high
chromium group, but without any statistical significance (Striffler et aI., 1998).
During hyperinsulinemia, chromium may have an indirect effect on body weight.
Weight gain can occur in hyperinsulinemic subjects, and the magnitude of chromium
action on insulin is proportional to the body fat content. On the other hand, chromium
supplementation resulted in an increase in lean body mass and these changes tended to
be greater in older subjects (Anderson, 1998). However, chromium action in improving
glucose tolerance may be limited to those subjects with chromium deficiency (Anderson,
1988). Besides, effective action of chromium on glucose tolerance and CVD risk
factors depends also on appropriate timing and dosage (Mertz, 1993).
Mechanism of Chromium's action on Insulin
The mechanism of chromium's effect on lipid metabolism is not clear (Mertz,
1993; Abraham et aI., 1992). It was hypothesized that chromium helps control blood
glucose concentration by increasing insulin action (Anderson et aI., 1997). Chromium
was reported to minimize the amount of insulin needed by tissues for glucose utilization
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and to decrease insulin secretion in NIDDM patients (Offenbacher & Pi-Sunyer, 1980).
It was hypothesized that chromium has a greater effect on individuals who are glucose
intolerant (Riales & Albrink, 1981)
Decreased sensitivity of pancreatic ~ cells to circulating glucose leads to insulin
overproduction, which in tum down regulates the sensitivity of the peripheral tissue to
insulin. Chromium was reported to reverse these compensatory changes in pancreatic P
cells, by increasing the sensitivity of the peripheral tissue to insulin and thus decreasing
insulin requirements (Striffler et al., 1995). It is suspected that chromium binds to
insulin receptors in peripheral tissues to improve insulin action (Mertz, 1993). On the
other hand, chromium was also reported to increase the sensitivity of pancreatic ~ cells
to circulating glucose level. The result is a decrease in glucose tolerance and in the risk
factors for CVD (Anderson et aI., 1997). Chromium was also reported to enhance the.
insulin hepatic clearance, which helps reduce the circulating insulin concentration
(Striffler et aI., 1995). Consequently, through its effect on glucose metabolism,
chromium may have some effect on serum lipids (Anderson et aI., 1997).
In case of adequate chromium stores, chromium would be released from stores
following a glucose load challenge to facilitate insulin action on peripheral tissues. This
explains the increase in circulating chromium concentration following a glucose
challenge. In case of chromium deficiency, a decrease in circulating chromium is
reported to compensate for the poor storage. This is done to keep the physiological
action of insulin on peripheral tissues. However, when circulating chromium is not
adequate for normal insulin function, insulin resistance may appear (Mertz, 1993). It
was reported that some of the changes seen after chromium supplementation are
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transitory and that extended supplementation over a relatively longer time will revert
those changes to the pretreatment period (Abraham et al., 1992).
Chromium has been hypothesized to bind to calmodulin at the intracellular level,
and the presence of chromium bound calmodulin may be required for the activation of
cAMP-dependent phosphodiesterase (cAMP-OPE). As a consequence, activated
cAMP-OPE inhibits the action of pancreatic cAMP to secrete insulin. The result is a
decrease in the hyperactivity of pancreatic ~ cells, which reduces insulin secretion
(Striffler et al., 1995).
Due to the associated risk of cancer development (Barrett-Connor & Grady,
1998) chromium may be an alternative to hormonal replacement therapy. The low cost
and the lack of side effects make it a preferred lipid lowering agent over other therapies
(Lee & Reasner, 1994). However, the lack of standardized tests to assess body
chromium status makes it difficult to determine the healthy young adults who may suffer
from subclinical chromium deficiency, and whose chromium intake may help reduce the





Institutional Review and Investigators Training
This study was approved by the Institutional Review Board (IRB) for human
subjects at Oklahoma State University (Appendix A). In addition, the principal
investigator and the research assistants involved in this study attended training sessions
on laboratory safety, including biohazard and radioactive material.
Subjects Solicitation
After approval of Oklahoma State University, volunteers were recruited by
announcements through University mailings, local newspapers, and contact with
churches, senior citizen organizations, and local stores (Appendix B). Solicited women
subjects were postmenopausal, with elevated total cholesterol, and not on estrogen
replacement therapy.
Supplement Preparation
Supplements for this study were prepared in the Department of Nutritional
Sciences laboratory at Oklahoma State University. Number two gelatin capsules
(Apothcary Product, Inc., Minneapolis, MN) were filled using a gelatin capsule filler
machine (Quanterron, Inc,. Burnsville, MN).
Placebo capsules contained approximately 0.1970 g U.S.P. grade lactose
(Spectrum Quality Product, Inc. Gardene, CAl. The chromium supplementation
consisted of 2.653 g U.S.P. grade CrCl).6H20 (Professional Compounding Centers of
America, Inc. Houston, TX) in 982.437 g U.S.P. grade lactose. so that 0.1970 g of
chromium supplement mixture was calculated to contain 100 ~g chromium as
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CrCi).6H20. The lactose and CrCh.6H20 were mixed together for 8 hours in a ball
mixture to obtain a homogeneous distribution of chromium in lactose.
The chromium and placebo supplements were analyzed for chromium content
using atomic absorption spectrophotometer, Model 5100 PC (Perkin-Elmer Corp.,
Norwalk, CT). Ten 0.1 g randomly chosen samples from the placebo and chromium
supplement mixtures were wet and dry ashed using a modification of the Hill et al.
method (Hill et al., 1986). The average analyzed chromium content of the placebo was
-2.1 J.1g1g lactose. The average analyzed chromium content of the chromium supplement
was 288.72 J.1g1g of chromium supplement mixture. Since the analyzed chromium
concentration was lower than calculated values, the filled weight of the chromium
supplement mixture was adjusted to 0.346 g per capsule in order to provide 100 J.1g
chromium per capsule.
Experimental Design
A pre-test, experimental treatment, post-test design was used for this study (Ott,
1977a). Volunteer subjects were screened for serum total cholesterol concentration
three weeks prior to starting the study to ensure they had an elevated serum cholesterol
concentration. Pre and post-data collections were performed at the beginning and the
end of twelve-week supplementation.
Data Collection
Screen
At the screen, subjects signed an informed consent (Appendix C) after it was
verbally explained to them by the principal investigator. Subjects also completed a
Health Questionnaire to assess their health status and medication use (Appendix D).
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Subjects were trained by the principal investigator on how to complete a one week food
frequency questionnaire (Appendix E).
Subjects received a baseline supplement which was the lactose placebo, to take
for three weeks between the screen and the pre-data collection. Subjects were instructed
to take two supplements each day. one with a morning meal and one with an evening
meal. The purpose of the baseline supplement was to allow the subjects to adjust to
taking the study supplements twice a day.
Pre-data Collection
At the pre-data collection, subjects brought in a complete one week food
frequency questionnaire for their food intake the week before the pre-data collection.
Subjects carne in following a twelve-hour fast, but were instructed to consume water.
Subject's weight was measured to the nearest pound. A licensed phlebotomist drew a
fasting blood sample in two separate 7.5 ml serum tubes (Monovette, Germany), after
which the subjects were asked to sit for 20-30 minutes, where they were provided with
nutritional support in the form of orange juice, muffins and coffee.
The subjects were provided with a one-month supply of the randomly assigned
supplement and instructed to take two capsules each day, one in the morning and one in
the evening with meals. The second and the third month's supply of supplements were
delivered to the subjects individually. Volunteer subjects received $50 for their
participation in the study.
Post-data collection
At the end of the twelve-week supplementation period, subjects returned for the
post-data collection following a twelve-hour fast period. Subjects brought in a second
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completed one-week food frequency questionnaire for their food intake the week prior to
the post-data collection. Subject's weight was measured to the nearest pound. A
licensed phlebotomist drew a fasting blood sample in two separate 7.5 ml serum tubes.
After the blood collection subjects were asked to sit for a period of 20 to 30 minutes for
nutritional support.
Blood Analysis
The same blood handling techniques were followed in both the pre and the post-
data collection. After drawing the blood, the serum tubes were allowed to sit in an ice
bath for 30 minutes. The tubes were centrifuged for 20 minutes at a speed of 10,000
rpm to separate the serum. The serum was transferred to individual 0.5 mJ storage tubes,
covered with parafilm and stored at -20°C for future analysis of total cholesterol, HDL-
cholesterol, TG, apo A-I, apo B, glucose, insulin and estradiol. LDL-cholesterol
concentration was calculated.
Total cholesterol, HDL-cholesterol, TG, apo A-I, apo B and glucose were
determined using enzymatic methods adapted for the COBAS-FARA clinical analyzer
(COBAS FARA, Roche. Diagnostic System, Inc. Montclair, NJ). Insulin and estradiol
were analyzed using radioimmunoassay (Diagnostic Products Corporation, Los Angeles,
CA) counted on the Packard Cobra II gamma counter.
Total cholesterol was detennined using Roche method kit number 44307. The
principle of this technique is based on the release of cholesterol from its esters by the
enzymatic action of an ester hydrolase, then by oxidizing the free cholesterol with
oxidase and producing hydrogen peroxide. The hydrogen peroxide, under the action of
aminoantipyrine and phenol, forms a chromophore, quinoneimine in a proportional
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amount to the cholesterol concentration. Quinoneimine is detennined photometrically at
500nm.
HDL-cholesterol was determined using Roche method kit number 44136. The
principle is based on the precipitation of chylomicrons, VLDL and LDL by the action of
phosphotungstic acid and magnesium and a subsequent centrifugation, which keeps the
HDL in the supernatant. HDL cholesterol is then collected and detennined by a
cholesterol reagent similar to that of total cholesterol detennination.
TG was detennined using Roche method kit number 44119. The principle is
based on the hydrolysis of TG by lipoprotein lipase to glycerol and fatty acids. Glycerol
is then phosphorylated to glycerol 3-phosphate, which is then oxidized to form
dihydroxiaceton phosphate and hydrogen peroxide. Hydrogen peroxide reacts with
aminophenazone and chlorophenol to fonn quinoneimine in a proportional quantity to
TG concentration. Quinoneimine is detennined photometrically at 490-500 nm.
Apo A-I was determined using Roche method kit number 44162. The method is
based on the precipitation of apo A-I using sheep antiserum. The precipitate is then
measured at 340 nm.
Apo B was determined using Roche method kit number 44161. The method is
based on the precipitation of apo B with a rabbit antiserum. The precipitate is then
measured at 340 nm.
Glucose was determined using Roche method kit number 47382. The method is
based on the phosphorylation of glucose to glucose 6-phosphate. In the presence of
NAD, glucose 6-phosphate is oxidized to 6-phosphogluconate, while NAD is reduced to
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NADH. NADH production is proportional to the glucose concentration and can be read
at 340nm.
LDL cholesterol was calculated using the following fonnula:
LDL cholesterol =Total cholesterol - (HDL + TO/5 ) (Friedewald et aL, 1972).
Insulin was determined using a radioimmunoassay competitive Coat-A-Count
method (Diagnostic Products Corporation, Los Angeles, CA). The method is based on
competition for an antibody, for a fixed time, between 125I_labeled insulin and sample
insulin. The antibody is immobilized on the wall of an assay tube. After incubation, the
labeled insulin fraction bound to the tube wall is isolated by decanting the supernatant.
A Packard Cobra IT gamma counter and a calibration curve then determine the sample
insulin.
Estradiol was determined using a radioimmunoassay competitive Coat-A-Count
method (Diagnostic Products Corporation, Los Angeles, CA). The method is based on
a competition for an antibody, for a fixed time, between 125I-Iabeled estradiol and
sample estradiol. The antibody is immobilized on the wall of the tube. After incubation.
the labeled estradiol fraction bound to the tube wall is isolated by decanting the
supernatant. A Packard Cobra IT gamma counter is used to determine the amount of
labeled estradiol, which is inversely proportional to the estradiol concentration in the
sample.
Dietary Record Analysis
A seven day food frequency questionnaire was used to assess the subjects'
dietary intake (Eck et al., 1991). The questionnaire by Eck et al., was a modification of
Willett's one year food frequency questionnaire, which was tested for reliability and
30
validity (Eck et al., 1991). The subjects' seven day food frequency questionnaires were
analyzed and averaged using the Food Processor Plus Program (version 7.11, ESHA
Research, Salem OR). The subjects' seven day food frequencies were analyzed and
averaged for daily intake of kilocalories, protein(g) carbohydrate(g), fiber(g), fat(g) and
cholesterol(mg), and the percent of calories from carbohydrate, protein, total and
saturated fat.
Data Analysis
Age, weight, BMI, average dietary intake, serum lipids, apolipoproteins, glucose,
insulin and estradiol concentrations were compared between groups at baseline to see if
there were any differences between the groups at baseline. Changes in serum lipid
concentrations and apolipoproteins (total cholesterol, LDL-cholesterol, HDL-
cholesterol, apo A-I, apo B, and TG), serum glucose, serum estradiol and serum insulin
concentrations after twelve weeks of supplementation were compared to changes in the
placebo group after twelve weeks supplementation. Data were analyzed using the
Statistical Analysis System (SAS) general linear model procedure (GLM). Average pre
and post dietary intakes were compared within each group to determine if there were any
significant changes in dietary intakes within supplement groups during the twelve weeks
supplementation, using the SAS repeated measures procedure. Significance level was




The aim of this study was to investigate the effects of twelve-week chromium
supplementation on serum lipids, apolipoproteins, glucose, insulin, and estradiol among
hyperlipidemic postmenopausal women not using estrogen replacement therapy.
Nineteen subjects initially volunteered for the study. One subject was dropped because
she did not meet the study criteria, one subject was dropped due to poor compliance
taking the supplement, one subject was dropped because of a poor blood draw I and two
subjects were 'dropped because they were diabetic. Thus the data represented fourteen
subjects, seven in the placebo group, and seven in the chromium supplemented group.
Subjects' Age and Anthropometric Measurements
Subjects' mean age and anthropometric measurements by supplement group are
presented in Table I. The mean age of the placebo group was 58 years. The mean age
of the chromium group was 60 years. There was no significant difference at baseline
between the two groups in age. The placebo group had a mean height of 166 cm while
the chromium group had a mean height of 161 cm. There was also no significant
difference in height between the two groups at baseline.
At baseline, the placebo group had a mean body weight of 79.0 kg, and a mean
body mass index (EMI) of 28.6 kg/m2. The chromium group had a mean body weight of
84.5 kg, and a mean BMI of 32.4 kg/m2. After twelve weeks of supplementation, the
placebo group had a mean body weight of 80.8 kg and a BMI of 29.3 kg/m2, while the




Subject's Age and Anthropometric Measurement/
Placebo Chromium
Age (years)
oWeeks (Baseline) 58 ± 4 60 + 5
Height (em)
oWeeks (Baseline) 166 ± 1 161 ± 2
Body Weight (kg)
oWeeks (Baseline) 79.0 ± 3.9 84.5 ± 6.7
After 12 Weeks Supplementation 80.8 ± 3.5 79.9 ± 2.2
RMI (kglm2)
oWeeks (Baseline) 28.6 ± 1.6 32.4 ± 2.3
After 12 Weeks Supplementation 29.3 + 1.5 30.7 ± 0.8
IMeans ±standard error.
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weights of both groups were above average compared to height in both groups
(Metropolitan Height-Weight Tables, 1994). Also both groups are considered
overweight also because their BMIs were above 27.3 kglm2 (Kuczmarski, 1998). There
were no differences between the two groups in body weight and BM! at baseline. In
addition there were no significant changes within each group in pre and post body
weight and BMI.
Subjects' Seven Day of Dietary Intake
Subjects' mean pre and post seven-day dietary intakes are reported in Table II.
There were no significant differences in mean dietary intakes between the two groups at
baseline. In addition, there were no significant changes within each group between pre
and post mean dietary intakes.
Energy
The mean kilocalorie intake of the placebo group at was 1835 kcal and that of
the chromium group was 1614 kcal. There was no significant difference in the
kilocalorie intake at baseline between the two groups. After supplementation the mean
caloric intake of the placebo group was 1632 kcal and that of the chromium group was
1558 kcal. There was also no significant change within each group between the pre and
post mean kilocalorie intake. The recommended energy intake for women with an age
of 51 years and older is 1900 kcal (Ausman & Russell, 1994). The mean caloric intake
of both groups at baseline was below the recommendation, and the mean caloric intake
of both groups after supplementation was also below the recommendation. The
anthropometric data showed that both groups had high mean BMIs before and after
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TABLEll
Subjects' Average Seven Day Dietary Intake}
Pla.cebo Chromium
Kiloca.lories
oWeeks (Baseline) 1835 + 257 1614 ± 151
After 12 Weeks Supplementation 1632 ± 269 1558 ± 182
Carbohydrates (g)
oWeeks (Baseline) 213 ± 30 189 ± 24
After 12 Weeks Supplementation 201 ± 29 186 + 24
Protein (g)
oWeeks (Baseline) 79 ± 11 70 ± 7
After 12 Weeks Supplementation 71 ± 12 71 ± 8
Total Fat (g)
oWeeks (Baseline) 67 + 15 65 ± 6
After 12 Weeks Supplementation 61 ± 14 59 ± 7
Saturated Fat (g)
oWeeks (Baseline) 24 ± 3 20 ± 2
After 12 Weeks Supplementation 20 ± 4 20 ± 3
Cholesterol (mg)
oWeeks (Baseline) 214 ± 39 187 ± 38





Subject's Average Seven Day Dietary Intake) (Continued)
Placebo Chromium
Fiber (g)
oWeeks (Baseline) 17 + 3 14 ± 2
After 12 Weeks Supplementation 14 ± 3 15 ± 3
% Calories from Carbohydrate
oWeeks (Baseline) 48 ± 2 46 ± 3
After 12 Weeks Supplementation 51 ± 2 48 + 2
% Calories from Protein
aWeeks (Baseline) 19 ± 1 18 ± 1
After 12 Weeks Supplementation 17 + 1 18 ± 1
% Calories from Total Fat
oWeeks (Baseline) 33 ± 5 36 + 2
After 12 Weeks Supplementation 32 ± 3 34 + 2
% Calories from Saturated Fat
oWeeks (Baseline) 12 ± 1 12 ± 2




supplementation. However the mean caloric intakes of both groups were below the
recommendation. This may be the result of underreporting total energy intake by the
subjects due to underrepresentation of some food groups in the questionnaire (Eck et aI.,
1991).
Carbohydrate
The mean carbohydrate intake for the placebo group at baseline was 213 g and
that of the chromium group was 189 g. There was no significant difference between the
two groups at baseline. After supplementation the mean carbohydrate intake was 201 g
for the placebo group and 186 g for the chromium group. In addition, there was no
significant difference in mean carbohydrate intake within each group between pre and
post supplementation. There is no Recommended Dietary Intake for carbohydrate
(Ausman & Russell, 1994). However the median carbohydrate intake, derived from one
day dietary recalls, for white women aging 60 to 69 years is 185 g and that of black
women is 180 g for the same age group (Kuczmarski, 1998). The carbohydrate intake
for both groups was above the median intake.
Protein
The mean protein intake of the placebo group at baseline was 79 g and the mean
protein intake of the chromium group was 70 g. There was no significant difference in
mean protein intake between the two groups at baseline. The mean protein intake of the
placebo group after supplementation was 71 g and that of the chromium group was 71 g.
There was also no significant change in mean protein intake within each group between
the pre and post supplementation. The Recommended Dietary Intake for protein is 50
g/day for females aging 51 years and older (Kuczmarski, 1998). The mean protein
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intake for both groups at baseline and after supplementation was ,above the
recommendation.
Total and Saturated Fat
At baseline, the mean total fat intake was 67 g and the mean saturated fat intake
was 24 g in the placebo group. For the chromium group the mean total fat intake was 65
g and the mean saturated fat intake was 20 g at baseline. There was no significant
difference at baseline between the two groups in mean total or saturated fat intake. After
supplementation mean total fat intake for the placebo group was 61 g and the mean
saturated fat intake was 20 g. For the chromium group, the mean total fat intake was 59
g and the mean saturated fat intake was 20 g after supplementation. There was also no
significant change within each group in mean total or saturated fat intake between pre
and post supplementation. No Recommended Dietary Allowance is set for total fat
intake (Ausman & Russell, 1994). The median of total fat intake, derived from one-day
dietary recalls, is 55 g for white women age 60 to 69 years and 45 g for black women.
The median saturated fat intake for both categories of women are 18 and 14 g
respectively (Kuczmarski, 1998). The mean pre and post total saturated fat intakes for
both the placebo and chromium groups were above the median intake.
Percent of Calories From Carbohydrate, Protein and Fat
The percent of calories from carbohydrate, protein and fat are reported in Table
n. The percent of calories from carbohydrate at baseline was 48 for the placebo group
and 46 for the chromium group. No significant difference in percent of calories from
carbohydrate was observed at baseline between the two groups. After supplementation
the percent of calories from carbohydrate was 51 for the placebo group and 48 for the
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chromium group. There was also no significant change in the percent of calories from
carbohydrate within each group between pre and post supplementation.
The percent of calories from protein at baseline was 19 for placebo group and 18
for the chromium group. There was no significant differenae in percent of calories from
protein between the two groups at baseline. After supplementation the percent of
calories from protein was 17 for the placebo group and 18 for the chromium group.
There were also no significant changes, within each group in the percent of calories
from protein between pre and post supplementation.
At baseline the percent of calories from total fat was 33 for the placebo group
and 36 for the chromium group. The percent of calories from saturated fat was 12 for
both the placebo and the chromium group at baseline. There were no significant
differences between the two groups at baseline in the percent of calories from total or
saturated fat. After supplementation, the percent of calories was 32 from total fat and 11
from saturated fat for the placebo group, and 34 from total fat and 12 from saturated fat
for the chromium group. There were no significant changes within each group in the
percent of calories from total or saturated fat between pre and post supplementation.
The percent of calories from carbohydrate at baseline in both groups was below
the recommended percent of calories from carbohydrate, which is 50 to 60 % (National
Cholesterol Education Program, 1994). After supplementation, the placebo group was
close to the lower end of the recommended intake range, but the chromium group
remained below the recommendation range. The percent of calories from protein was
adequate in both groups before and after the supplementation, since the recommended
intake for protein is 10 to 20 % of calories (National Cholesterol Education Program,
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1994). The percent of calories from total fat in both groups before and after the
supplementation was above the recommendation of less than 30 % of calories from total
fat (National Cholesterol Education Program, 1994). In addition, the percent of calories
from saturated fat for both groups at baseline and after supplementation was above the
recommendation of less than 10 % of calories from saturated fat (National Cholesterol
Education Program, 1994).
Cholesterol
The mean intake of cholesterol at baseline for the placebo group was 214 mg and
that of chromium group was 187 mg. There was no significant difference in mean
cholesterol intake between the two groups at baseline. After supplementation the mean
cholesterol intake for the placebo group was 196 mg and that for the chromium group
was 217 mg. There was no significant change in mean cholesterol intake within the two
groups between pre and post supplementation. Cholesterol intake in both groups before
and after supplementation was within the recommendation, which is less than 300 mg
(Kuczmarski, 1998).
Fiber
The mean fiber intake at baseline was 17 g for the placebo group and 14 g for the
chromium group. There was no difference at baseline between the two groups in mean
fiber intake. After supplementation the mean fiber intake was 14 g for the placebo and
15 g for the chromium group. There was also no significant change in mean fiber intake
within the two groups between pre and post supplementation. Fiber is reported to have a
hypocholesterolemic effect and an intake above 18 glday is recommended. Fiber intake
above 18 glday is hypothesized to reduce serum cholesterol by 5 % (Schneeman &
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Tietyen, 1994). The mean pre and post fiber intake for both groups was below this
recommendation.
Effect of Chromium Supplementation on Serum Lipids and Apolipoproteins
Subjects' serum lipid and apolipoprotein concentrations before and after 12
weeks of supplementation are presented in Table m. At baseline, the placebo group had
a total cholesterol concentration of 239 mg/dl. A total cholesterol concentration greater
than 240 mg/dl is considered high risk for CVD (Kuczmarski, 1998). Thus, the placebo
group appeared to be on the borderline of high risk for CVD. The placebo had an LDL
cholesterol concentration of 180 mg/dl at baseline. This value is also considered a high
risk for CVD since an WL cholesterol concentration above 160 mg/dl is considered
high risk (Kuczmarski, 1998). The placebo group had an HDL cholesterol concentration
at baseline of 29 mg/dI. An HDL cholesterol concentration below 35 mg/dl is
considered a high risk for CVD (Kuczmarski, 1998). Thus the mean HDL cholesterol
concentration for the placebo indicates a risk factor for CVD. The mean TO
concentration for the placebo group at baseline was 148 mg/dl. The TO concentration of
the placebo group at baseline can be classified normal since a TG concentration below
200 mg/dl is classified desirable (Feldman, 1994). The baseline concentration of apo A-
I for the placebo group was 143 mg/dl. The average value for apo A-I concentration for
women aging 60 to 64 is 135 mg/dl (Feldman, 1994), and thus the baseline
concentration of apo A-I for the placebo group is close to normal. The apo B
concentration for the placebo group at baseline was 133 mg/dl. This is considered a risk
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TABLEffi
Effect ofChromium Supplementation on Serum Lipids and ApolipoproteinsJ
Placebo Chromium
Total Cholesterol (mg/d!)
oWeeks (Baseline) 239 ± 11 a 299 ± 23 b
After 12 Weeks Supplementation 230 ± 11 244 ± 16 *
LDL-cholesterol (mg/d})
oWeeks (Baseline) 180 ± 11 213 ± 22
After 12 Weeks Supplementation 170 ± 12 177 + 12
HDL-cholesterol (mg/dl)
oWeeks (Baseline) 29 ± 2 34 ± 2
After 12 Weeks Supplementation 28 ± 1 30 ± 3
Triglycerides (mg/d\)
oWeeks (Baseline) 148 ± 17 260 ± 36
After 12 Weeks Supplementation 161 + 19 185 ± 30 *
Apolipoprotein A-I (mg/dl)
oWeeks (Baseline) 143 ± 13 148 ± 28
After 12 Weeks Supplementation 154 ± 17 155 ± 25
Apolipoprotein B (mgldl)
oWeeks (Baseline) 133 ± 23 155 ± 7
After 12 Weeks Supplementation 119 ± 23 135 ± 21
IMeans ± standard error.
3Values with different superscript letters in a row are significantly different at baseline, p
<0.05.
*Change in concentration after 12 weeks in chromium supplemented group significantly
different compared to change in placebo after 12 weeks, p < 0.05.
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factor for CVD since the average apo B concentration for this population segment is 100
mg/dl (Feldman, 1994).
At baseline the chromium group had a total cholesterol concentration of 299
mg/dl. Thus, the chromium group would be considered at high risk for CVD because its
total cholesterol concentration was above 240 mg/dl (Feldman, 1994). The chromium
group had an LDL cholesterol concentration of 213 mg/dl at baseline. Thus, the
chromium group's mean LDL cholesterol concentration would be considered high risk
because it was above 160 mg/dl (Feldman, 1994). The mean HDL cholesterol
concentration of the chromium group at baseline was 34 mg/dl. The mean HDL-
cholesterol concentration for the chromium group was near the recommended
concentration for HDL cholesterol, which is 35 mg/dl (Feldman, 1994). The TO
concentration of the chromium group at baseline was 260 mgldl. The range for mild to
moderate hypertriglyceridemia is 250 to 700 mg/dl (Feldman, 1994), and thus the
chromium group would be classified in the category of mild to moderate
hypertriglyceridemia at baseline (Feldman, 1994). The apo A-I concentration of the
chromium group at baseline was 148 mg/dl which was above the normal concentration
of 135 mg/dl (Feldman, 1994). The apo B concentration of the chromium group at
baseline was 155 mgldl. This apo B concentration is aboveloo mg/dl, which would be
considered as a risk factor for CVD (Feldman, 1994).
At baseline the mean total cholesterol concentration for the chromium group was
significantly higher than the mean cholesterol concentration for the placebo group.
However, no significant differences were observed at baseline between the two groups
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for other serum lipids and apolipoproteins (lDL cholesterol, HDL cholesterol, TG, apo
A-I and apo B).
After twelve weeks of supplementation a significant decrease in serum total
cholesterol concentration was observed in the chromium group compared to the placebo
group. The post supplementation concentration of total serum cholesterol for the
chromium group was 244 mg/d) and that of the placebo was 230 mg/dl. It is important
to note that the serum total cholesterol concentration of the chromium group was
significantly higher than the placebo group at baseline, and this may have affected the
results. The results of the current study concerning a significant decrease in total
cholesterol are in agreement with many chromium supplementation studies (Anderson et
aI., 1997; Offenbacher & Pi-Sunyer, 1980; Press et aI., 1990; Elwood et al ., 1982).
Twelve-week chromium supplementation resulted in a larger trend to decrease
LDL cholesterol concentration compared to the placebo group (p = 0.07). The post
supplementation concentration of LDL cholesterol for the chromium group was 177
mg/dl and that of the placebo was 170 mgldI. Press et al. reported a significant decrease
in LDL cholesterol after chromium supplementation (Press et aI., 1990). However,
many studies reported an insignificant decrease in LDL cholesterol following chromium
supplementation (Thomas & Gropper, 1996; Potter et aI., 1985; Uusituipa et aI., 1992;
Abraham et aI., 1982; Donaldson et aI., 1985).
There was also no significant change in serum HDL cholesterol concentration
within the two groups after twelve-week supplementation. The post supplementation
concentration of the HDL cholesterol for the chromium group was 30 mgldl and that of
the placebo group was 28 mg/dl. However, there was a trend towards a decrease in
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HDL cholesterol in both groups. Contrary to the current study, HDL cholesterol was
reported to significantly increase in many studies following chromium supplementation
(Abrahamet al., 1992; Elwood et aI., 1982; Riales & AlbJink 1981). Even though HDL
is reported to be more sensitive to chromium supplementat10n than total cholesterol
(Riales & Albrink 1981), a significant increase in HDL cholesterol was not expected
because the mean HDL cholesterol concentration of both groups at baseline was above
the recommended range.
Chromium supplementation also resulted in a significant decrease in serum TG
compared to the placebo. The TG concentration after chromium supplementation was
185 mgldl and that of the placebo was 161 mgldl. For the chromium supplemented
group, the mean TG concentration at baseline was in the range of mild to moderate
hypertriglyceridemia. After twelve-week chromium supplementation the mean TG
concentration was within normal range. The change in TG is also in agreement with
other studies that have reported a significant decrease in mean TO concentration with
chromium supplementation (Abraham et aI., 1992; Lee & Reasner, 1994; Riales &
Albrink, 1981).
No significant difference in apo A-I concentration was observed after twelve-
week chromium supplementation compared to the placebo group. The apo A-I
concentration after supplementation was 155 mgldl for the chromium group and 154
mgldl for the placebo group. However, apo A-I concentration tended to increase in both
groups. In contrast to the current results, one study reported that apo A-I significantly
increased following supplementation with 200 llglday of chromium (Press et aI., 1990).
However, in this study, apo A-I at baseline was within normal range and thus a
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significant increase was not expected. There was also no significant change observed in
apo B concentration within the chromium supplemented group compared to the placebo.
The post supplementation concentration of apo B was 135 mg/dl for the chromium
group and 119 mg/dl for the placebo group. However, apo B tended to decrease in both
groups. One study reported that apo B significantly decreased with chromium
supplementation (Press et aI., 1990).
Effect of Chromium Supplementation on Serum Glucose. Insulin and Estradiol
Subjects' mean pre and post supplementation serum glucose, insulin and
estradiol concentrations are reported in Table IV. For the placebo group, the mean
fasting serum glucose concentration was 101 mg/dl at baseline. This is considered
within normal range because a fasting plasma glucose below 115 mg/dl is considered
normal (Kuczmarski, 1998). The placebo group also had a mean fasting serum insulin
concentration of 13 IlIU/ml at baseline. This is almost at the upper limit of the normal
fasting insulin range, which is lO-12lJ.IU/ml (Glascow, 1990). The serum estradiol
concentration for the placebo group at baseline was 70 pg/ml Serum estradiol is not
tightly regulated and variation in circulating concentrations is common (Schiff, 1990).
Women with an average age of 48 year were defined as early perimenopausal and
reported to have a mean circulating estradiol concentration of 107.3 pg/ml. Women
with and average age of 50 years were defined as late perimenopausal reported to have a
mean circulating serum estradiol of 48.0 pg/ml. Women with and average age of 51
years were defined as early postmenopausal and reported to have a mean circulating




Effect ofChromium Supplementation on Serum Glucose, Insulin and Estradiol}
Placebo Chromium
Glucose (mg/dl)
oWeeks (Baseline) 101 ± 1 113 ± 5
After 12 Weeks Supplementation 99 ± 3 101 ± 4
Insulin (uIU/ml)
oWeeks (Baseline) 13 ± 1 12 ± 1
After 12 Weeks Supplementation 12 ± 2 14 ± 3
Estradiol (pg/ml)
oWeeks (Baseline) 70 ± 19 46 ± 11
After 12 Weeks Supplementation 60 + 9 71 ± 29
1Means ± standard error.
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late postmenopausal and reported to have a mean circulating serum estradiol of
24.7pg/ml (Slemenda, 1987).
For the chromium group, the mean fasting serum glucose concentration at
baseline was 113 mg/dl. Similarly to the placebo group, this concentration is also within
the nonnal range for fasting serum glucose. The mean fasting serum insulin
concentration for the chromium group was 12 ~/ml at baseline. This concentration
was also within the nonnal range. The chromium group had a serum estradiol
concentration of 46 pg/ml at baseline. There were no significant differences at baseline
between the two groups in serum glucose, insulin and estradiol.
There was a small decrease in serum glucose after twelve week of chromium
supplementation compared to the placebo group. However, this decrease was
insignificant. The post supplementation concentration of fasting serum glucose was 101
mg/dl for the chromium and 99/mg/dl for the placebo. A significant decrease in the
mean fasting serum glucose was not expected because the mean fasting glucose
concentration in the chromium group at baseline was within the nonnal range. Some
studies have reported that serum glucose decreased with chromium supplementation
(Anderson et aI., 1997; Riales & Albrink, 1981; Li, 1994; Offenbacher & PI-Sunyer,
1980). However, other studies have reported no effect on serum glucose following
chromium supplementation (Abraham et aI., 1992; Wilson & Gondy, 1995). Chromium
status at baseline may be a detenninant for chromiums' action on glucose tolerance (Lee
& Reasner, 1994). As mentioned earlier, the subjects of the current study had a fasting
serum glucose within normal range.
48
--
In this study insulin concentration did not significantly change after twelve
weeks of chromium supplementation compared to the placebo. The post
supplementation insulin concentration for the chromium group was 14 J1IU/ml and that
of the placebo was 12 IlIU/ml. Serum insulin has been reported to significantly decrease
with chromium supplementation (Wilson & Gondy, 1995; Offenbacher & Pi-Sunyer,
1980; Riales & Albrink, 1981; Anderson et aI., 1997). On the other hand, other studies
have reported similar results to the current study, observing no significant effect on
fasting serum insulin with chromium supplementation (Wilson & Gondy, 1995; Thomas
& Gropper, 1996). Subjects with relatively higher fasting serum insulin appeared to
benefit more from chromium supp.ementation (Wilson & Gondy, 1995). In this study
serum insulin was not expected to decrease in the chromium group because the baseline
serum insulin concentration was within the normal range.
In this study, mean serum estradiol concentration did not significantly change
after twelve weeks chromium supplementation compared to the placebo. The mean
estradiol concentration after supplementation was 71 pg/ml for the chromium group and
60 pg/ml for the placebo group. Both post supplementation estradiol concentrations
were above the concentration of the late postmenopausal group. However, this may be
due to the high variation in the observed values.
The absence of the chromi urn effect on serum glucose, insulin and estradiol may
be due to sample size. The sample size in the current study was small. It is a well
known fact that a small sample size will decrease statistical power. Loss of power is one
reason for not having a statistical significance, since sample size is usually calculated to
detect significant differences between treatments, which in this study, are chromium
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versus placebo. Therefore in many cases, it is difficult to show significant differences
when the planned sample size is not reached (Ott, 1977b). As a result, careful
consideration should be given when interpreting the results of the current study due to
the small sample size.
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CHAPTER V
SUMMARY, RECOMMENDATIONS AND CONCLUSION
The purpose of this study was to investigate the effects of twelve-week
chromium supplementation on serum lipids and apolipoproteins (total cholesterol, LDL
and HDL cholesterol, TO, apo A-I and apo B), serum glucose, insulin and estradiol, in
hypercholesterolemic postmenopausal women. With the approval of the Institutional
Review Board, this study was conducted in the spring and summer of 1998, using
fourteen postmenopausal women from the community of Stillwater and surrounding
area.
Subjects were randomly assigned to one of two groups. The placebo group
consumed a lactose placebo for twelve weeks. The chromium group consumed 200 ~g
per day chromium in the form of CrCh.6H20 in lactose for twelve weeks. All subjects
were independently living and consumed self-selected diet throughout the study.
Height, weight, and twelve-hour fasting blood samples were obtained at baseline.
Weight and twelve-hour fasting blood samples were also obtained after twelve weeks of
supplementation. The subjects also completed a health questionnaire and a seven day
food frequency at each data collection.
Changes after twelve weeks in serum lipids, glucose, insulin and estradiol in the
placebo group were compared to changes in the chromium group. Seven day food
frequencies were used to evaluate dietary intake. Dietary parameters included in the
dietary analysis were total calories, protein, total and saturated fat, cholesterol, fiber, and
percent of calories from carbohydrates, protein and total and saturated fat.
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Mter twelve weeks chromium supplementation, a significant decrease in serum
total cholesterol and triglycerides was observed compared to the placebo. In addition,
there was a trend towards a decrease in serum LDL cholesterol concentration after
twelve weeks chromium supplementation compared to the placebo.
CONCLUSION
The first null hypothesis Ho 1 stated that there would be no significant effect due
to twelve weeks supplementation with 200 Ilglday of chromium on serum lipids (total
cholesterol, HDL-cholesterol, LDL-cholesterol, and TO) and apolipoproteins (apo A-I,
apo B). The first null hypothesis was rejected because twelve weeks supplementation
with 200 Ilg of chromium decreased serum total cholesterol and TO concentrations,
compared to the placebo. No significant effects were observed on LDL and HDL
cholesterol, apo A-I and apo B. However, HDL cholesterol and apo A-I were initially
within normal ranges and no changes were expected.
The second null hypothesis flo 2, stated that there would be no significant effect
due to twelve weeks supplementation with 200 Ilg/day chromium on serum insulin and
serum fasting glucose. The second null hypothesis was accepted because there were no
significant effect due to twelve weeks supplementation with 200 Ilg chromium on serum
insulin and serum fasting glucose concentrations compared to the placebo.
The third null hypothesis Ho 3 stated that there would be no significant effect due
to twelve weeks supplementation with 200 Ilglday chromium on serum estradiol. The
third hypothesis was accepted because there was no significant effect due to twelve
weeks supplementation with 200 Ilg of chromium on serum estradiol compared to the
placebo.
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Due to the observed results in this study, it seems that a chromium intake at the
ESADDI, from either a dietary source or a supplementary source may help reduce some
risk factors for the development of CVD among postmenopausal hypercholesterolemic
women. However the mechanism for the effect of chromium on serum lipids is
unknown. In this study, the theory that the effect of chromium on se.rum lipids is
mediated through an action on serum insulin was not observed. The absence of any
significant effect of chromium on fasting serum glucose, insulin or estradiol may be due
to the fact that subjects in this study were not insulin resistant or may be due to the small
sample size.
RECOMMENDATIONS
Based on the results of this study, it is recommended that:
1. future studies use a larger sample size;
2. future studies should check the accuracy of the balance before subjects are weighed;
3. future studies be conducted on hyperlipidemic NIDDM patients to investigate the
theory that individuals with NIDDM are the most likely to benefit from chromium
supplementation;
4. future studies investigate the effect of various amounts and forms of chromium;
5. future studies include an assessment of dietary chromium intake;
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Did you know that the risk of heart disease increases
for women after menopause?
Would you like to know if adequate chromium and copper lower blood cholesterol and hean
disease risk among women after menopause?
Volunteers will receive $ 50 for participating in this study.
We have an opportunity for women if you are:
• Past menopause
• Have high blood cholesterol, over 200 mgldl
• Not using estrogen replacement therapy
• Not using medication to lower blood cholesterol
This study will investigate the effects and interactions of chromium and copper supplementation on the risk of
cardiovascular disease in postmenopausal women. The aims of this study are to detennine if twelve weeks
supplementation with chromium, copper or a combination of chromium and copper lowers blood cholesterol
and other indicators of heart disease risk in post-menopausal women.
Volunteers will be given either a placebo, chromium, copper, or a combination of chromium and copper.
Volunteers will be asked to take one supplement each morning and one each evening with meals for twelve
weeks. The total daily intake is 3 mg copper and 200 I!g/day chromium, which are the upper level of the safe
and adequate intake range for each nutrient, as set by the National Research Council, Food and Nutrition Board.
Volunteers will participate in fasting blood and early morning urine collections. A light breakfast will be served
after the fasting blood collection. Volunteers will also participate in routine measurements of wrist. waist and
hip circumferences. skin fold, height and weight. Volunteers will be asked to keep diet records before blood
collections.
This study has been approved by the Institutional Review Board For Proteetion of Human Subjects at
Oklahoma State University and is funded by the Oklahoma Center For the Advancement of Science and
Technology.
Sound Like Fun??? If you are interested or for further information please contact:
Janice R Hermann. PhD, RD/LD
Andrea B Arquitt, PhD, RO/LD










Individual Consent to Participate in Research
Women's Cholesterol Study: Effect and interactions of chromium and copper on lipid
metabolism in hypercholesterolemic post menopausal women
I, • voluntarily agree to participate in the above titled
research which is sponsored by Agriculture Experiment Station, College of Human
Environmental Sciences at Oklahoma State University.
I understand that:
(1) the purpose of the study id to measure the effects of mineral supplementation on
plasma lipids and trace mineral status in post menopausal women;
(2) I will receive supplement containing ONE of the following:
(a) 0.25 mg lactose as a placebo
(b) 1.5 mg copper
(c) 100 Jlg chromium
(d) 1.5 mg copper plus 100 llg chromium
(3) I will take one supplement with each morning and evening meal for 12 weeks;
(4) I will not take any new vitamin or mineral supplement other than those that are part
of the study
(5) a phlebotomist will draw fasting blood samples of 30 mI (about 6 teaspoons) by
venipuncture at the beginning and the end of the study, and that slight bruising or discomfort
may result from the venipuncture;
(6) my blood wilJ only be used for the study protocol. and any remaining blood tissue
will be discarded and no further tests will be run;
(7) a urine sample will be collected al the beginning and the end of the study;
(8) routine data will be collected or measured for age. height. body weight, wrist, waist
and hip circumferences at the beginning and end of the study;
(9) I will complete a Health Questionnaire concerning health conditions, medication use.
vitamin and mineral supplement use and exercise practices at the beginning of the study;
and a follow-up health and exercise questionnaire after each month of supplementation;
(10) I will complete a 7 day food frequency questionnaire at the beginning and end of
supplementation;
(11) as a reward for participation and as an incentive to complete the study, Jwill receive
$25 at both the beginning and end blood collections.
(12) all records are confidential and that my name will not be associated with any reports
or data records at the end of the study;
(13) participation is voluntary and that J have the right to withdraw from the study at
any time by contacting the principal investigators;
(14) J will withdraw from the project if a need to begin taking medication for my health
during the study;
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(15) this research is beneficial to the public in that the risk of cardiovascular di ease
increase among women after menopause;
(16) I may contact Dr Janice Hermann or Dr Andrea Arquitt or Dr Barbara Stoecker at
(405) 744-5040 should I wish further infonnation. rmay also contact the office of
University Research Services, 001 Life Scinces East, Oklahoma State University,
Stillwater. OK 74078 telephone (405) 744-5700.
1have read and fully understand the consent form. I sign il freely and voluntarily. A
copy has been given 10 me.
Date ------ _ Time----------
Signed ------------------------
I certify that I have personally explained all elements of this form to the subject before
requesting the subject to sign it.
Signed ---- _
(project director or her authorized representative)
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1. Subject Number ----
2. Date of Birth
3. Do you have or have you bad any of the foUowing condition?













4. Do you Currently take any medications on a regular basis? No Yes
Specify all medications taken on a regular basis:
Name How often perdayOr-- per week
Name How often perdayOr-- per week
Name How often perdayOr__ per week
Name How often perdayOr__ per week
Name How often perdayOr__ per week
Name How often perdayOr__ per week
Name How often per day Or per week
5.What types of exercise do you do on a regular basis?
How many times a week do you exercice? ----------
How many minutes would you estimate your exercise in a week? - _
6. Height cm Weight _
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Vitamin and Mineral Supplement
1. Do you take any vitamin or mineral supplement(s)? Yes No
2. if Yes. please. list all names of vitamin or mineral supplements. and how often
do you take the supplement(s)?
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How ofteo per day Or per week
Seven Day Food Frequency Questionnaire
'This questionnaire asks you about your consumption of foods and beverages over
the past week. The "How Often" columns are for day. day. week. or rarely/never. We
want you to think back over the past week and tell us how many times (per day or
per week) you consumed each item. A medium serving is in parenthesis.
EXAMPLES:
Ate Y2 grapefruit about twice last week.
Ate 1 large hamburger four times Iasl week.
Drank 2 cups of whole milk each day.
Typeortood How Orten Size
(Medium Serving) Day Week Rarely/ S M L
Never
Grape Fruit (In) 2 X
Hambur.l!er. reRular (I patty. 3 oz) 4 X
Whole milk (I cUP. 8oz) 2 X
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Tomato iuice (112 CUD)
Tomato saucelll2 cun)
Spa2heni sauce (1/2 CUD)
Red chilli sauce, taco sauce, or salsa
(1 ThSD)
Tofu or Sovbean (3-4()z)
StriniZ beans, IZreeII beaDs (1/2 CUD)
Broccoli (1/2 cuD)
Cabbue 0/2 CUD)
Cole slaw (1/2 cUi))
Cauliflowerll/2 cun)
Brussels SDl'OUts 0/2 CUD)
Carrots, raw (1/2 carrot or 2-4 sticks)
Carrots, cookedlll2cup)
Com (I ear or1/2 CUD frozen or canned)
Peas (1/2 CUD fresh, frozen or canned)
Uma beans lI/2 CUD frozen or canned)
Mixed vepetables-O/2 CUD)
Beans or lentils, baked or dried (1/2 CUD)
Summer or vellow souashC112 CUD)
Winter sauash 1I/2 CUD)
Zucchini (1/2 CUD)
Yam or sweetMtatofl/2 CUD)
SDinach (cookedll2 CUD, raw I CUD)
Ice bur2 lettuce, romaine or leaf (I CUD)
Celerv (4" stick)
Beets (1/2 cUD)
Alfalfa sorouts (1/2 CUD)
Kale, mustard, or chard 2reens (1/2 CUD)
Vegetable, vegetable beef, minestrone
or tomato SOUD ( CUD)
7'2
Type of Food HowOnen Size
(Medium SeniDg)
Day Week Rarely! S M L
Never
BREAD CEREALS STARCH I
Cold breakfast cereal (1 cup)
Cold cereal breakfast-fortified (I CUD)
Cooked oatmeal (1 CUD)
Other cooked breakfast cereal ( I CUD)
White bread (J slice)
Pita bread (1 Diece)
Dark bread (l slice)
Ensilisb muffin (I)
Ba2el (Il
Dinner roll (I )
Hambur2er or ooidal!. bUD (I)
Muffin (1)
Biscuit (1)
Com bread, com muffin (1)
Brown rice (J CUD)
White rice (I CUD)
Soa2hetti noodles (I cup)
Macaroni noodles (l cup)
Other Dasta noodles (l CUD)
Bul2ar. kasba. couscous (lcUD)
Pancakes or waffles (2)
Potatoes. frensb fries or fried (1/2 CUD)
Potatoes. backed or boiled ( I)
Mashed ootatoes (I cup)
Potato chips or com chips
(small bait or 1 oz)
Saltine crackers (S)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (5)
Other cracker, low fat (5)
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(Medium Serving)




Chicken or turkey, roasted or broiled
with skin (3-4 oz)
Chicken or Illrkey, roasted or broiled
skinless 0-4 oz\




Sausal/:e (2 Datties or 2 linkes)
Bolol1:Da (J slice)
Other processed luncheon meat (I slice\
Liver, chicken or beef (3-4 oz)
Hambunrer. fC2UlarCI DattY, 3-4 OZ)
Hambuner, lean (lDattv, 3-4 oll
Meat loaf (3-4 OZ)
Pork, ChODS, roasts (3-4 OZ)
Lamb (3-4 OZ)
Beef, roast.. steak (3-4 oz)
Beef stew withvelletables (I CUD)
Ham (3-4 oz)
Tuna fish(3-4 oll
Tuna salad (In cuD)
Fish, backed or broiled/3-4 oll
Fish, fried or fish sa.ndwich (3-4 oz)
Shrimp, Lobster, ScalloDs
Pizza (2 slices)
Mixed dishes wilh cheesell CUD)
LasalIDa or meat oasta dishes (l CUD)
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Apples, applesauce or pears
(1 fresh. \12 CUD)
ADDIe iuice (1/2 CUD)
Oran~es
Oran~e iuice (1/2 CUD)
Graoefruit (1/2 cu
GraDefruit iuice (1/2 CUD)
Other fruit iuices(1/2 CUD)
Strawbenies-fresh. frozen, or canned
(1/2 CUll)
Bluebenies-fresb. frozen. or canned
(1/2 cup)
Peaches (I fresh. \12 CUD canned)
Aoricots () fresh, \12 CUD canned}
Plums (I fresh. \12 CUD canned)
Honeydew melon (1/4 melon)
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(Medium Serving)




Chocolate (] small bar or 1 oz)
Candv bar (Ismall bar)
Candv without chocolate(} oz.)
Cookies. home baleed (2)
Coolcies, ready made (2)
Brownies (2)
Do.uts(2)
Cake. home baleed (lslice)
Calee, ready made (I slice)
Sweet roll, coffee calee. or other
oaslrv readY made (] servin!!)
Sweet roll, coffee calee. or other
oaslrv home baked (l serviolZ)
Pie. homemade (l slice)
Pie, readv made (lslicel




POOCOTD, air ooooed (I cup)
Nuts(small oacke! or I OZ) ,
Bran, added 10 fcodel Thsp)
Wh.eat "erm (] Thso)
Chowder or cream SOUD (] cun)
Oil and vioel!a1' dressiol! (I Thsp)
Mayonoaise or other creamy salad
dressinl! (] Thso)
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